Literature DB >> 24047703

Higher fecal bile acid hydrophobicity is associated with exacerbation of dextran sodium sulfate colitis in mice.

Lotta K Stenman1, Reetta Holma, Richard Forsgård, Helena Gylling, Riitta Korpela.   

Abstract

Increased luminal bile acid hydrophobicity is associated with cytotoxicity and has been suggested to contribute to gut barrier dysfunction. The aim of this study was to compare 2 high-fat diets and a low-fat diet as to whether they modify fecal bile acid profile and hydrophobicity and/or susceptibility to dextran sodium sulfate (DSS) colitis in C57Bl/6J mice. Control and DSS-Control groups received a low-fat control diet [5.5% of total energy (E%) soy oil, 4.5 E% lard], and the DSS-Lard (5.5 E% soy oil, 54.5 E% lard) and DSS-Fish oil (5.5 E% soy oil, 27.2 E% lard and 27.2% menhaden oil) groups received high-fat diets. Feces for bile acid analysis were collected after 3-wk feeding, followed by induction of dextran DSS colitis (2 d 5% DSS in drinking water + 2 d tap water). Fecal bile acid hydrophobicity was elevated 76% in the lard group (P = 0.051) and 122% in the fish oil group (P = 0.001) compared with control, indicating potentially increased cytotoxicity. DSS caused severe colitis symptoms, evaluated as rectal bleeding, whereas all the controls were symptom free. The median symptom scores were: DSS-Control, 2.3 (IQR = 0.6, 3.0); DSS-Lard, 0.3 (IQR = 0, 2.3); and DSS-Fish oil, 2.4 (IQR = 1.9, 2.8). The only differences were DSS-Control vs. control (P < 0.001) and DSS-Fish oil vs. control (P < 0.001). Severity of symptoms in all colitic mice was positively correlated with fecal bile acid hydrophobicity (Spearman's ρ = 0.43; P = 0.028) and fecal deoxycholic acid concentration (Spearman's ρ = 0.39; P = 0.048). These results suggest that luminal bile acid modification, induced by altered dietary fat composition, may alter susceptibility to DSS colitis.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24047703     DOI: 10.3945/jn.113.180810

Source DB:  PubMed          Journal:  J Nutr        ISSN: 0022-3166            Impact factor:   4.798


  12 in total

1.  Tauroursodeoxycholic acid inhibits experimental colitis by preventing early intestinal epithelial cell death.

Authors:  Debby Laukens; Lindsey Devisscher; Lien Van den Bossche; Pieter Hindryckx; Roosmarijn E Vandenbroucke; Yves-Paul Vandewynckel; Claude Cuvelier; Brigitta M Brinkman; Claude Libert; Peter Vandenabeele; Martine De Vos
Journal:  Lab Invest       Date:  2014-10-13       Impact factor: 5.662

2.  Ursodeoxycholic Acid and Its Taurine- or Glycine-Conjugated Species Reduce Colitogenic Dysbiosis and Equally Suppress Experimental Colitis in Mice.

Authors:  Lien Van den Bossche; Pieter Hindryckx; Lindsey Devisscher; Sarah Devriese; Sophie Van Welden; Tom Holvoet; Ramiro Vilchez-Vargas; Marius Vital; Dietmar H Pieper; Julie Vanden Bussche; Lynn Vanhaecke; Tom Van de Wiele; Martine De Vos; Debby Laukens
Journal:  Appl Environ Microbiol       Date:  2017-03-17       Impact factor: 4.792

Review 3.  Taurocholic acid metabolism by gut microbes and colon cancer.

Authors:  Jason M Ridlon; Patricia G Wolf; H Rex Gaskins
Journal:  Gut Microbes       Date:  2016-03-22

4.  Deoxycholic Acid-Mediated Sphingosine-1-Phosphate Receptor 2 Signaling Exacerbates DSS-Induced Colitis through Promoting Cathepsin B Release.

Authors:  Shengnan Zhao; Zizhen Gong; Xixi Du; Chunyan Tian; Lingyu Wang; Jiefei Zhou; Congfeng Xu; Yingwei Chen; Wei Cai; Jin Wu
Journal:  J Immunol Res       Date:  2018-05-09       Impact factor: 4.818

Review 5.  IBD and Bile Acid Absorption: Focus on Pre-clinical and Clinical Observations.

Authors:  Leo R Fitzpatrick; Paniz Jenabzadeh
Journal:  Front Physiol       Date:  2020-06-12       Impact factor: 4.566

6.  Defective humoral immunity disrupts bile acid homeostasis which promotes inflammatory disease of the small bowel.

Authors:  Ahmed Dawood Mohammed; Zahraa Mohammed; Mary M Roland; Ioulia Chatzistamou; Amy Jolly; Lillian M Schoettmer; Mireya Arroyo; Khadija Kakar; Yuan Tian; Andrew Patterson; Mitzi Nagarkatti; Prakash Nagarkatti; Jason L Kubinak
Journal:  Nat Commun       Date:  2022-01-26       Impact factor: 17.694

7.  The Nonsteroidal Anti-Inflammatory Drug Ketorolac Alters the Small Intestinal Microbiota and Bile Acids Without Inducing Intestinal Damage or Delaying Peristalsis in the Rat.

Authors:  Barbara Hutka; Bernadette Lázár; András S Tóth; Bence Ágg; Szilvia B László; Nóra Makra; Balázs Ligeti; Bálint Scheich; Kornél Király; Mahmoud Al-Khrasani; Dóra Szabó; Péter Ferdinandy; Klára Gyires; Zoltán S Zádori
Journal:  Front Pharmacol       Date:  2021-06-04       Impact factor: 5.810

8.  Deoxycholic Acid Triggers NLRP3 Inflammasome Activation and Aggravates DSS-Induced Colitis in Mice.

Authors:  Shengnan Zhao; Zizhen Gong; Jiefei Zhou; Chunyan Tian; Yanhong Gao; Congfeng Xu; Yingwei Chen; Wei Cai; Jin Wu
Journal:  Front Immunol       Date:  2016-11-28       Impact factor: 7.561

Review 9.  Dextran sodium sulfate colitis murine model: An indispensable tool for advancing our understanding of inflammatory bowel diseases pathogenesis.

Authors:  Derrick D Eichele; Kusum K Kharbanda
Journal:  World J Gastroenterol       Date:  2017-09-07       Impact factor: 5.742

10.  IL-13 as Target to Reduce Cholestasis and Dysbiosis in Abcb4 Knockout Mice.

Authors:  Luisa Hahn; Nora Helmrich; Diran Herebian; Ertan Mayatepek; Uta Drebber; Eugen Domann; Stefan Olejniczak; Markus Weigel; Torsten Hain; Timo Rath; Stefan Wirtz; Hans-Joachim Mollenkopf; Nadine Schmidt; Christa Ewers; Anne Baier; Yuri Churin; Anita Windhorst; Ralf Weiskirchen; Ulrich Steinhoff; Elke Roeb; Martin Roderfeld
Journal:  Cells       Date:  2020-08-24       Impact factor: 6.600

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.